Table 9 Adverse events in each group while on ATT
|  | HIV + (n = 150) | HIV- (n = 155) | Overall (n = 305) |
|---|---|---|---|
Total patients experiencing adverse event(s) | 69 (46.0%) | 74 (47.7%) | 143 (46.9%) |
Total patients experiencing serious adverse event(s) | 44 (29.3%) | 3 (1.9%) | 47 (15.4%) |
IRIS* | 14 (9.3%) | 0 | 14 (4.6%) |
Anaemia (new on treatment)* | 9 (6.0%) | 0 | 9 (3.0%) |
Drug-induced hepatotoxicity* | 5 (3.3%) | 0 | 5 (1.6%) |
Isoniazid-induced psychosis* | 1 (0.7%) | 0 | 1 (0.3%) |
Stevens-Johnson syndrome* | 1 (0.7%) | 0 | 1 (0.3%) |
Peripheral neuropathy* | 2 (1.3%) | 0 | 2 (0.7%) |
Haemoptysis* | 0 | 6 (3.9%) | 0 |
Itch | 9 (6.0%) | 2 (1.3%) | 11 (3.6%) |
Rash | 11 (7.3%) | 2 (1.3%) | 13 (4.3%) |
Nausea/vomiting | 47 (31.3%) | 71 (45.8%) | 118 (38.7%) |
Diarrhoea | 17 (11.3%) | 24 (15.5%) | 41 (13.4%) |
Abdominal pain | 17 (11.3%) | 26 (16.8%) | 43 (14.1%) |